HemoTypeSC, a low-cost point-of-care testing device for sickle cell disease: Promises and challenges.


Centre of Excellence for Sickle Cell Disease Research & Training, University of Abuja, Abuja, Nigeria. Electronic address: [Email]


Sickle cell disease (SCD) is a neglected burden of growing importance. >312,000 births are affected annually by sickle cell anaemia (SCA). Early interventions such as newborn screening, penicillin prophylaxis and hydroxyurea can substantially reduce the mortality and morbidity associated with SCD. Nevertheless, their implementation in African countries has been mostly limited to pilot projects. Recent development of low-cost point-of-care testing (POCT) devices for sickle haemoglobin (HbS) could greatly facilitate the diagnosis of those affected.


HemoTypeSC,Low-cost,Newborn screening,Point-of -care -test devise,Sickle cell disease,

OUR Recent Articles